Get the Stockscreener App
73.42
0.08%
0.085
Dexcom Inc stock is traded at $73.42, with a volume of 4.10M.
It is up +0.08% in the last 24 hours and up +8.63% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$73.34
Open:
$73.215
24h Volume:
4.10M
Relative Volume:
0.66
Market Cap:
$28.63B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
51.40
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+3.78%
1M Performance:
+8.63%
6M Performance:
-17.52%
1Y Performance:
-16.14%
1-Day Range:
$71.84
$73.45
1-Week Range:
$70.75
$75.97
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
73.40 | 28.60B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
107.43 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.28 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.41 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.36 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.49 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Y Intercept Hong Kong Ltd Purchases New Position in DexCom, Inc. $DXCM - MarketBeat
Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments - Yahoo Finance UK
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time. - Business Wire
INVESTOR NOTICE: Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. (NASDAQ - marketscreener.com
CIBC Asset Management Inc Has $10.51 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
12 Best US Stocks to Buy and Hold in 2026 - Insider Monkey
Mitsubishi UFJ Trust & Banking Corp Sells 102,717 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Purchased by Sector Gamma AS - MarketBeat
Rakuten Investment Management Inc. Buys New Position in DexCom, Inc. $DXCM - MarketBeat
How Investors Are Reacting To DexCom (DXCM) Revenue Guidance After G7 Recall and CGM Expansion Plans - simplywall.st
Jennison Associates LLC Has $678.98 Million Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Teacher Retirement System of Texas Acquires 92,643 Shares of DexCom, Inc. $DXCM - MarketBeat
Baillie Gifford & Co. Sells 823,027 Shares of DexCom, Inc. $DXCM - MarketBeat
New DexCom CEO Remains Focused on Addressing Recent Quality Issues - Morningstar
DexCom Inc (DXCM) Trading 4.47% Higher on Jan 22 - GuruFocus
Campbell & CO Investment Adviser LLC Has $629,000 Holdings in DexCom, Inc. $DXCM - MarketBeat
Allstate Corp Invests $964,000 in DexCom, Inc. $DXCM - MarketBeat
Dexcom Reports 22% Revenue Growth to $1.2 Billion in 2024 Amidst Challenges - Intellectia AI
1 Growth Stock Down 19% to Buy Right Now - Finviz
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
FDA Flags Serious Software Issue in Dexcom Glucose Monitoring App - Drugwatch.com
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail
DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern - Chartmill
Fisher Funds Management LTD Sells 91,159 Shares of DexCom, Inc. $DXCM - MarketBeat
Market Pulse: Can DexCom Inc be the next market leader2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum And Conflicting Fair Value Signals - Yahoo Finance
Dexcom (DXCM) releases preliminary, unaudited results for Q4 2025 - MSN
Is Dexcom the Next Sleeper Stock? The Real Talk on This Glucose Tech Giant - AD HOC NEWS
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Here's why you should hold DexCom stock in your portfolio for now - MSN
Pinnacle Financial Partners Inc Sells 33,980 Shares of DexCom, Inc. $DXCM - MarketBeat
Stephens Investment Management Group LLC Sells 16,732 Shares of DexCom, Inc. $DXCM - MarketBeat
Nordea Investment Management AB Boosts Stake in DexCom, Inc. $DXCM - MarketBeat
Is DexCom Stock Underperforming the S&P 500? - MSN
DexCom Stock Declines Following Strong Preliminary Q4 Results - Yahoo Finance
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - Finviz
MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM - MarketBeat
How Do Investors Really Feel About DexCom Inc? - Benzinga
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Dexcom CEO Talks G8 CGM Sensor - Medical Device and Diagnostic industry
Palmetto Grain Brokerage - Palmetto Grain Brokerage
DexCom's Q4 2025 Earnings: What to Expect - Yahoo Finance
Dexcom’s new CEO talks affordability, over-the-counter glucose sensors - Healthcare Brew
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech - MassDevice
DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Insider Monkey
Dexcom’s Jake Leach on the future of continuous glucose monitoring - Modern Healthcare
Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness - Yahoo Finance
RWC Asset Management LLP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Bought by PKO Investment Management Joint Stock Co - MarketBeat
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Sells 17,554 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):